Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding share holdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to a specific insider transaction notification and does not contain financial performance data.
Material Changes
The filing details an increase in the holding of Ordinary Shares by a connected person, Dr. S Dexter, connected to Director Dr. P J T Vallance. The increase of 138 shares resulted from the re-investment of a dividend paid on October 4, 2012, and the purchase of shares at a price of 1456 pence per share on October 5, 2012.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly reports on the compliance notification of the share transaction under Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Verify the share price of 1456 pence per share on October 5, 2012, against market data.
- Confirm the total shareholding of Dr. S Dexter post-transaction.
- Review the dividend payment date of October 4, 2012, to validate the reinvestment timing.